Los Angeles Times

Commentary: Prevent a legal Catch-22 that could push thousands of generic drugs off the market

Many have debated the role of patents in the present drug pricing crisis, the authors write.

Carvedilol could be the poster child for how to lower drug prices. Since 2007, more than 20 million patients with cardiovascular conditions have enjoyed generic versions of the popular beta-blocker, which cost 2 cents a dose compared with $4.81 for the brand-name product. Patents on the drug Coreg, dating back to 1978, have long expired, enabling these price-saving generics.

Yet this year, a federal jury deemed one generic carvedilol maker in violation of a patent to the tune of $235

You’re reading a preview, subscribe to read more.

More from Los Angeles Times

Los Angeles Times5 min read
There's A New Highly Transmissible COVID-19 Variant. Could FLiRT Lead To A Summer Uptick?
Two new COVID-19 subvariants, collectively nicknamed FLiRT, are increasingly edging out the winter's dominant strain ahead of a possible summer uptick in coronavirus infections. The new FLiRT subvariants, officially known as KP.2 and KP.1.1, are beli
Los Angeles Times3 min read
Alleged Violin Thief Also Robbed A Bank, Prosecutors Say, With Note That Said 'Please' And 'Thx'
LOS ANGELES — The violins were expensive — and very, very old. They included a Caressa & Francais, dated 1913 and valued at $40,000. A $60,000 Gand & Bernardel, dated 1870. And a 200-year-old Lorenzo Ventapane violin, worth $175,000. For more than tw
Los Angeles Times2 min readWorld
Facing A 'National Emergency,' South Korea President Urges Citizens To Have More Babies
SEOUL, South Korea — South Korean President Yoon Suk Yeol announced this week that he would create a new government ministry to tackle the country's low birth rate, which he called "a national emergency." The ministry will serve as a specialized "con

Related Books & Audiobooks